Funding. Early phase trial CLIP2, Institut National du Cancer. IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric adenocarcinoma patients. Amount: 500,000 euros.